Prostate Cancer

Real-world evidence shows robust adherence rates and prostate-specific antigen response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

High adherence rates and favorable prostate-specific antigen response to apalutamide where seen in Patients with nonmetastatic castration-resistant prostate cancer.

Compared to those who are overweight or of a normal weight, patients who are obese are more likely to have better disease-specific and overall survival in metastatic castration-resistant prostate cancer.

In this companion article, Neeraj Agarwal, MD, discusses the role of genomic testing and imaging in the initial diagnosis, staging, and treatment of prostate cancer.

Alicia K. Morgans, MD, PhD, discusses the cardiovascular risks associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

Smruthy Sivakumar, PhD, discusses a large-scale analysis of comprehensive genomic profiling utilization and ancestral characterization of the genomic landscape in patients with advanced prostate cancer.

P-PSMA-101, an autologous CAR-T product for the treatment of metastatic castrate-resistant prostate cancer, produces a durable response.

In this first video of the series, Neeraj Agarwal, MD, of the Huntsman Cancer Institute of the University of Utah explains the role of imaging and genomic testing in the diagnosis and treatment of prostate cancer.

In a 75-year-old patient with metastatic castration-resistant prostate cancer, a bone scan taken at 14-month follow-up showed evidence of 2 lesions in the right hip/pelvis, and abdominal/pelvic CT showed a 2.1-cm left pelvic lymphadenopathy.

Six months after being diagnosed with stage T2N0MO prostate cancer, a 75-year-old patient showed a 2.1-cm left pelvic lymphadenopathy on an abdominal/pelvic CT.

During a Targeted Oncology Cased-Based Roundtable event, Chandler Park, MD, t discussed the case of a 75-year-old patient with metastatic castration-resistant prostate cancer.

Dr Evan Y. Yu shares sequencing strategies for LuPSMA radioligand therapy in patients with PSMA-positive mCRPC.

Evan Y. Yu, MD, reviews the phase 2 TheraP trial evaluating PSA response in patients with PSMA-positive mCRPC who received LuPSMA therapy vs cabazitaxel.

Dr Evan Y. Yu reviews the use of 177Lu-PSMA-617 therapy in patients with progressive PSMA-positive mCRPC as seen in the phase 3 VISION trial.

Evan Y. Yu, MD, shares insight on the rationale for precision medicine in patients with progressive PSMA-positive metastatic castration resistant prostate cancer (mCRPC) who have been previously treated with androgen axis inhibitor drugs and taxane.

Adding the targeted radioligand LuPSMA to standard of care therapy for patients with metastatic castration resistant prostate cancer after androgen receptor pathway inhibition and chemotherapy extended overall survival and delayed disease progression

Metastasis-free survival can be an effective end point in clinical trials to support approval of castration-resistant prostate cancer therapies under certain conditions when overall survival is not feasible as an end point.

To address over expression of the prostate specific membrane antigen in men with prostate cancer and other solid tumors, a phase 1 study of the novel anti-PSMA antibody drug conjugate, ARX517, has been administered to the first patient.

During a Targeted Oncology Case-Based Roundtable event, Tian Zhang, MD, MHS, an assistant professor of Medicine at Duke Cancer Institute, discusses the case of a 60-year-old patients with metastatic castration-resistant prostate cancer.

Jorge A. Garcia, MD, FACP, discussed that case of a 66-year-old female presented to a urologist with nodular 7-cm mass along posterior bladder wall and was later diagnosed with bladder cancer. He was joined by Neeraj Mahajan, MD, Anish B Parikh, MD, and 8 other physicians during a Targeted Oncology Case-Based Roundtable event.

Alan H. Bryce, MD, the chair of the Genitourinary Disease Group at the Mayo Clinic leads a Targeted Oncology Rountable Discussion on factors for choosing AR-targeted therapy for prostate cancer. He is joined by Robert Yoo, DO, Justin Goldfarb, DO, Miguel Gonzalez Velez, MD, Gehan Botrus, MD, Fei Gu, MD, Rajinder Grover, MD.

During a Targeted Oncology Case-Based Roundtable event, Joshi Alumkal, MD, discussed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.

A correlation between small cell or neuroendocrine carcinoma of the prostate and poor survival outcomes was revealed, despite treatment with the combination of the immunotherapy agent atezolizumab and chemotherapy, according to an institutional study conducted within the Mayo Clinic.

During a Targeted Oncology Case-Based Roundtable event, Alicia K. Morgans, MD, MPH, discussed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.

Samantha E. Greenberg, MS, MPH, CGC, discusses if the changes to the National Comprehensive Cancer Network’s Clinical Practice Guidelines for Prostate Cancer. NCCN has expanded germline testing in metastatic prostate cancer to all patients with high-risk, very high-risk, or regional prostate cancer.

Pedro C. Barata, MD, MSc, discussed the case of a 66-year0old woman with urothelial carcinoma during a Targeted Oncology Case-Based Roundtable event.

During a Targeted Oncology Case-Based Roundtable event, Thomas Hutson, DO, PharmD, discussed the case of a patient with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the health-related quality of life and patient-reported outcomes in the TITAN trial of apalutamide versus placebo patients with metastatic castration-sensitive prostate cancer.

In patients with progressive prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer receiving treatment in the phase 3 VISION trial, the addition of the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death versus SOC alone.

During a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, reviewed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.